Drug Search Results
More Filters [+]

Concizumab

Alternative Names: concizumab
Latest Update: 2024-12-03
Latest Update Note: News Article

Product Description

Concizumab is a monoclonal, humanized IgG4 antibody specific for the Kunitz-2 domain of Tissue Factor Pathway Inhibitor (TFPI). Preclinical studies in vitro or on animal models and in vivo have demonstrated the ability of concizumab to restore thrombin generation, promoting the establishment of a procoagulant action; all these results were subsequently confirmed in the studies of EXPLORER program. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020573/#:~:text=Concizumab%2C%20an%20anti%2Dtissue%20factor,Hemophilia.)

Mechanisms of Action: SPINT2 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novo Nordisk
Company Location: BAGSVAERD DENMARK G7 00000
Company CEO: Lars Fruergaard Jorgensen
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Concizumab

Countries in Clinic: Algeria, Australia, Austria, Bosnia, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Estonia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Lithuania, Malaysia, Mexico, North Macedonia, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, South Africa, Spain, Sweden, Switzerland, Thailand, Turkey, Ukraine, United Kingdom, United States

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Hemophilia A|Hemophilia B|Injuries/wounds Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NN7415-4616

P3

Unknown Status

Injuries/wounds Unspecified

2029-11-02

NN7415-4307

P3

Unknown Status

Injuries/wounds Unspecified

2026-06-09

EXPLORER 10

P3

Active, not recruiting

Injuries/wounds Unspecified

2026-04-05

NN7415-4311

P3

Unknown Status

Injuries/wounds Unspecified

2025-12-31

Recent News Events